Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)
Conditions
Interventions
valganciclovir
Locations
1
United States
Stanford University Medical Center
Stanford, California, United States
Start Date
May 1, 2007
Primary Completion Date
August 1, 2007
Completion Date
August 1, 2007
Last Updated
May 27, 2022
NCT04542161
NCT03759522
NCT05236465
NCT06952413
NCT05587777
NCT02374112
Lead Sponsor
Stanford University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions